Aptorum Group
APMAptorum Group is a publicly traded biopharmaceutical company dedicated to discovering and developing innovative therapies for diseases with significant unmet needs. Its strategy involves utilizing its proprietary platforms, including the ALS-4 platform for anti-infectives and the orphan drug-focused platform, to build a diversified pipeline. The company is advancing multiple candidates through early clinical stages while exploring strategic partnerships to accelerate development.
APM · Stock Price
Historical price data
AI Company Overview
Aptorum Group is a publicly traded biopharmaceutical company dedicated to discovering and developing innovative therapies for diseases with significant unmet needs. Its strategy involves utilizing its proprietary platforms, including the ALS-4 platform for anti-infectives and the orphan drug-focused platform, to build a diversified pipeline. The company is advancing multiple candidates through early clinical stages while exploring strategic partnerships to accelerate development.
Technology Platform
Proprietary platforms including the ALS-4 platform for repurposing drugs into anti-infectives and an orphan drug-targeted discovery platform, supported by computational screening methods.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ALS-4 + Placebo + ALS-4 + ALS-4 + Placebo | Healthy Subject | Phase 1 | |
| SACT-1 + EDURANT 25Mg Tablet | Healthy Subject | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Aptorum faces competition from large pharma and numerous biotechs in oncology and anti-infectives. Its differentiation is based on a drug repurposing strategy for faster development paths and focused platforms for anti-virulence and orphan diseases, though these approaches are also pursued by others.
